India draft drug patent rules target evergreening, generics
In short
India has issued draft drug patent guidelines. They would require strong scientific proof that a small drug change really improves how the medicine works, and they are meant to stop evergreening and help cheaper generics move faster.
This matters because drug companies may face stricter patent checks. The report did not say when the rules will take effect or which companies are affected.
What the reporting says
India issued draft guidelines requiring strict scientific proof of improved therapeutic efficacy for minor drug modifications. The rules are meant to curb evergreening and speed up cheaper generics, according to the published summary. The immediate consequence is tighter scrutiny of patent claims, but the final adoption timeline and any affected drug makers were not stated in the available reporting.
Why it matters
India’s draft drug-patent guidelines would require strict scientific proof that minor drug changes improve therapeutic efficacy. The stated aim is to curb evergreening and speed up cheaper generics, which could affect pharmaceutical companies that rely on incremental patent strategies. The summary does not state the final timing, scope, or specific companies affected.